The Benefits of LACRISERT®
Artificial tears and other products are less convenient for your patients because they require repeated applications.1-3 Just one LACRISERT® inserted in each eye once daily* can usually relieve Dry Eye symptoms.4
The dissolution of LACRISERT® begins within minutes of insertion, and lasts, on average, from 14 to 18 hours, providing all-day relief.4
Nontoxic, Preservative-Free Formula
LACRISERT® is well tolerated and has been approved for over 25 years.5 There are no preservatives, so your patient will not suffer from ocular sensitivity, irritation, or pain with continued use.1,4
LACRISERT® continuously releases a cellulosic polymer onto the ocular surface, thickening the tear film and extending the tear film break-up time (TFBUT) for continuous protection to the cornea and conjunctiva.4,6
Progressive visual deterioration, which occurs in some patients, may be retarded, halted, or sometimes reversed.4
Your patients may already be taking other treatments to control their Dry Eye symptoms. Fortunately, hydroxypropyl cellulose, the only ingredient in LACRISERT®, has no known drug interactions. It is therefore safe to use concomitantly with artificial tear products or any other Dry Eye treatment.4,7,8
With a little help from you, patients find the insertion process for LACRISERT® easy to learn. A study shows that 91% of rheumatoid arthritis patients learned to successfully place and retain the small insert after just a few tries.1
LACRISERT® is covered by most managed care plans. After you’ve written a prescription for LACRISERT®, you can rest assured that all he or she needs to do is drop his or her written prescription off at any local pharmacy. Tell your patients to visit here to get a $60 rebate coupon on the next LACRISERT® prescription.
This video will explain more about the benefits of LACRISERT®.
Click the following links for more information about patients’ experiences with LACRISERT®:
Indications and Usage
LACRISERT® is indicated in patients with moderate to severe Dry Eye syndromes, including keratoconjunctivitis sicca. LACRISERT® is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT® is also indicated for patients with exposure keratitis, decreased corneal sensitivity, and recurrent corneal erosions.
Important Safety Information
LACRISERT® is contraindicated in patients who are hypersensitive to hydroxypropyl cellulose. Instructions for inserting and removing LACRISERT® should be carefully followed. If improperly placed, LACRISERT® may result in corneal abrasion. Because LACRISERT® may cause transient blurred vision, patients should be instructed to exercise caution when driving or operating machinery. Patients should be cautioned against rubbing the eye(s) containing LACRISERT®.
The following adverse reactions have been reported, but were in most instances, mild and temporary: transient blurring of vision, ocular discomfort or irritation, matting or stickiness of eyelashes, photophobia, hypersensitivity, eyelid edema, and hyperemia.
*For most Dry Eye sufferers, one LACRISERT® inserted in each eye in the morning lasts the entire day. But some people may need to use it twice a day for symptom relief.4
References: 1. Hill JC. Slow-release artificial tear inserts in the treatment of dry eyes in patients with rheumatoid arthritis. Br J Ophthalmol. 1989;73(2):151-154. 2. Katz JI,
Kaufman HE, Breslin C, Katz IM. Slow-release artificial tears and the treatment of keratitis sicca. Ophthalmology. 1978;85(8):787-793. 3. Werblin TP, Rheinstrom SD, Kaufman HE. The use of slow-release artificial tears in the long-term management of keratitis sicca. Ophthalmology. 1981;88(1):78-81. 4. Lacrisert [prescribing information]. Lawrenceville, NJ: Aton Pharma, Inc; 2007. 5. Data on File. Aton Pharma, Inc.
6. Breslin CW, Katz J, Haufman HE, Katz I. Slow release artificial tears. In: Leopold IH, Burns RP, eds. Symposium on Ocular Therapy. New York, NY: John Wiley & Sons; 1977;10:77-83. 7. HØvding G, Aasved H. Slow-release artificial tears (SRAT) in dry eye disease: Report of a preliminary clinical trial. Acta Ophthalmol. 1989;59:842-846. 8. Bartlett JD, Jaanus SD, eds. Clinical Ocular Pharmacology. 4th ed. Boston, MA: Butterworth-Heinemann; 2001:325. 9. Lacrisert Clinical White Paper. Available at: http://www.lacrisert.com/attachments/LacrisertClinicalWhitePaper.pdf. Accessed January 5, 2009.